论文部分内容阅读
目的:系统评价托吡酯预防偏头痛的效果。方法:运用Cochrane系统评价方法,检索PubM ed(1990~2009)和CNK I数据库(1990~2009),筛选吡托吡酯预防偏头痛的随机对照试验(random ized controlled tria-le,RCT),并用RevM an5.0软件进行统计分析。结果:共初检出75篇文献,经筛选最终纳入7篇RCT进行分析,共2083例患者。M eta分析结果显示,安慰剂组与托吡酯组之间偏头痛的发作频率减少值比较,差异有统计学意义(Z=7.46,P<0.01)。结论:本系统评价结果显示,托吡酯比安慰剂更能减少偏头痛的发作频率。但由于本系统评价纳入的随机对照试验数目不多,有必要开展更多设计严谨,大样本、多中心的随机对照试验来确证这种趋势。
Objective: To systematically evaluate the effect of topiramate in preventing migraine. METHODS: Randomized controlled trials of topiramate (PMT) for the prevention of migraine were screened by PubMed (1990-2009) and CNKI (1990-2009) using the Cochrane systematic review method. RCMs of Rev MTa5 .0 software for statistical analysis. RESULTS: A total of 75 articles were initially detected and finally screened for inclusion in 7 RCTs for a total of 2083 patients. M eta analysis showed that there was significant difference in the reduction of migraine frequency between placebo group and topiramate group (Z = 7.46, P <0.01). Conclusion: This systematic review shows that topiramate reduces the frequency of migraine attacks more than placebo. However, due to the small number of randomized controlled trials included in this systematic review, it is necessary to conduct more rigorously designed, large sample, multicenter randomized controlled trials to confirm this trend.